Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 661-674

  Bodey, Bela ^a,e   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e NONE   (United States)

Author keywords

Autocrine stimulation; Bispecific monoclonal antibodies; Cancer immunotherapy; Cancer associated antigens; Clinical trials; Conjugated monoclonal antibodies; Drug antibody conjugates; Genetic engineering; Growth factor receptors; Growth factors; Human human monoclonals; Humanized mouse monoclonal antibodies; Immunotoxins; Interferon gamma; Mouse anti human monoclonal antibodies; Paracrine stimulation; Radionuclide conjugated monoclonal antibody

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYBRIDOMAS; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; NEOPLASMS; ONCOGENES;

EID: 0029994480     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (172)

1. Ehrlich P: Collected studies on immunity. Vol. II, John Wiley. New York, 1906.
2. Himmelweit B: The collected papers of Paul Ehrlich. Oxford: Pergamon Press, 1975.
3. Kufe DW, Nadler L, Sargent L, Shapiro H, Hand P, Austin F, Colcher D, Schlom J: Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res 43: 851-857, 1983.
4. Hakomori S, Kanagi R: Glycosphingolipids as tumor-associated and differentiation markers. J Nat Cancer Inst 71: 231-251, 1983.
5. Aziz KJ, Maxim PE Hackett JL, Tsakeris TM: Perspectives in laboratory management. Tumor markers: the premarket review and approval process. Am Clin Lab 1: 13-15, 1993.
6. Potter VR: On the road to the blocked ontogeny theory. Adv Oncol 4: 1-8, 1988.
7. Cho-Chung YS: Site-selective 8-chloro-cyclic adenosine 3′,5′-monophosphate as a biologic modulator of cancer: Restoration of normal control mechanisms. J Natl Cancer Inst 81: 982-987, 1989.
8. Rittenhouse HO, Manderino GL Hass GM: Mucin-type glycoproteins as tumor markers. Lab Med 16: 556-560, 1995.
9. Feizi T: Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are ancodevelopmental antigens. Nature (London) 314: 53-57, 1985.
10. Reisfeld RA, Cheresh DA: Human tumor antigens. Adv Immunol 40: 323-377, 1987.
11. Lloyd KO, Old LJ: Human monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the humoral immune response in cancer patients. Cancer Res 49: 3445-3451, 1989.
12. 131I-CC49 and interferon-gamma. Dis Colon & Rectum 37(2 suppl.): S100-S105, 1994.
13. Huebner RJ, Todaro GJ: Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci USA 64: 1087-1094, 1969.
14. Darlington DC: The plasmagene theory of the origin of cancer. Brit J Cancer 2: 118-126, 1948.
15. Kelly K, Siebenlist U: The regulation and expression of c-myc in normal and malignant cells. Ann Rev Immunol 4: 317-338, 1986.
16. Bishop JM, Baker B, Fujita D, McCombe P, Sheiness D, Smith K, Spector DH, Stehelin D, Varmus HE: Genesis of a virus-transforming gene. Natl Cancer Inst Monogr 48: 219-223, 1978.
17. Bishop JM: Oncogenes. Scientific American 246: 80-90, 1982.
18. Bishop JM: The molecular genetics of cancer. Science 235: 303-311, 1987.
19. Karess RE, Hayward WS, Hanafusa H: Transforming protein encoded by the cellular information of recovered avian sarcoma viruses. Cold Spring Harbor Symp Quant Biol 44: 765-77, 1979.
20. Klein G: The role of gene dosage and genetic transpositions in carcinogenesis. Nature (London) 294: 313-318, 1981.
21. Eva A, Robbin KC, Andersen PR, Srinivasan A, Tronick SR, Reddy Ellmare NW, Galen AT, Lautenberger JA Papas TS, Westin EH, Wong-Staal F, Gallo RC , Aaronson SA: Cellular genes analogues to retroviral one genes are transcribed in human tumour cells. Nature (London) 295: 116-119, 1982.
22. Ingraham CA, Cox ME, Ward DC, Fults DW, Maness PF: c-src and other proto-oncogenes implicated in neuronal differentiation. Mol Chem Neuropathol 89: 10: 1-14, 1989.
23. Dalla-Favera R Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM: Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Nat Acad Sci USA 79: 7824-7827, 1982.
24. Dalla-Favera R, Martinotti S Gallo RC, Erikson J, Croce CM: Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219: 963-967, 1983.
25. Mahaley MS, Gillespie GY: Immunologic considerations of patientswith brain tumors. In: Oncology of the nervous system. Walker MD (ed.), Boston, The Hague, Dordrecht, Lancaster: Martinus Nijhoff Publishers, The Netherlands, 1983, pp. 151-164.
26. Benveniste RE, Todaro GJ: Evolution of c-type viral genes: Inheritance of exogenously acquired viral genes. Nature (London) 252: 456-459, 1974.
27. Frisby DP, McCormick R, Weiss RA: Origin of RAV-O, the endogenous retrovirus of chickens. Cold Spring Harbor Conf. Cell Proliferation 7: 507-517, 1980.
28. Coffin J: Endogenous viruses. In: RNA tumor viruses, eds. Weiss RA Teich NM, Vars HE, & Coffin J Vol. 1., Cold Spring Harbor Laboratory, New York, 1982, pp. 1109-1203.
29. Jakobovits A: The expression of growth factors and growth factor receptors during mouse embryogenesis. In: Oncogenes and Growth control., eds. P. Kahn & T. Graf, Springer Verlag, Berlin-New York-Tokyo, 1986, pp. 9-17.
30. Weiner HL: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurg 37: 179-193, 1995.
31. Egan SE, Weinberg RA: The pathway to signal achievement. Nature (London) 365: 781-783, 1993.
32. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature (London) 313: 745-747, 1985.
33. Murray AW, Kirschner MW: Cyclin synthesis drives the early embryonic cell cycle. Nature (London) 9: 275-280, 1989.
34. Hall FL, Vulliet PR: Proline-directed protein phosphorylation. Current Opinion Cell Biol 3: 176-184, 1991.
35. Gazil A Igarishi H, Ciu IM: Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation. Cell 39: 89-97, 1985.
36. Glick RP, Gettleman R, Patel K, Kirtikumar P, Lakshman R, Tsibris JCM: Insulin and insulin-like growth factor 1 in brain tumors. Binding and in vitro effects. Neurosurg 24: 791-797, 1989.
37. Fleming TP Matsui T, Aaronson SA: Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Exp Gerontol 27: 523-532, 1992.
38. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53: 4550-4554, 1993.
39. Bar-Sagi D, Feramisco J, Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 42: 841-848, 1985.
40. Noda M, Ko M, Ogura A, Liu D, Amano T, Takano T, Ikawa Y: Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neural cell line. Nature (London) 318: 73-75, 1985.
41. Hagag N, Halegoua S, Viola M: Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21. Nature (London) 319: 680-682, 1986.
42. Tagliaferri P, Caraglia M, Muraro R, Pinto A, Budillon A, Zagonel V, Bianco AR: Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis fo cancer therapy. Anti-Cancer Drugs 5: 379-343, 1994.
43. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 308: 878-880, 1993.
44. Sporn MB, Todaro GJ: Autocrine growth factors and cancer. Nature (London) 313: 747-751, 1985.
45. Kohler G, Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature (London) 256: 495-497, 1975.
46. Songsivilai S, Lachmann PJ: Antibody engineering: Current status and future development. Asian Pacific J Allergy Immunol 8: 53-60, 1990.
47. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaem E, Van den Eynde, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
48. Houghton AN, Scheinberg DA: Monoclonal antibodies: potential applications to the treatment of cancer. Semin Oncol 13: 165-179, 1986.
49. Gabrilove JL: Differentiation factors. Semin Oncol 13: 228-233, 1986.
50. Talmadge JE Herberman RB: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70: 171-182, 1986.
51. Skerra A, Pluckthun A: Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240: 1038-1041, 1988.
52. Better M, Chang CP, Robinson RR, Horwitz AE: Escherichia coli secretion of an active chimeric antibody fragment. Science 240: 1041-1043, 1988.
53. Riechemann L, Foote J, Winter G: Expression of an antibody Fv fragment in myeloma cells. J Mol Biol 203: 82s-828, 1988.
54. Levy R, Miller RA, Stratte PT: Therapeutic trials of monoclonal antibody in leukemia and lymphoma: Biologic considerations. In: Boss BD, Langman R, Trowbridge I, et al. (eds). Monoclonal Antibodies and Cancer. Academic Press, Orlando, Florida 1983; pp. 5-16.
55. Herlyn D, Lubeck M, Sears H, Koprowski H: Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 85: 27-38, 1985.
56. Wong JH, Irie RF, Morton DL: Human monoclonal antibodies: Prospects for the therapy of cancer. Sem Surgical Oncol 5: 448-452, 1989.
57. Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, Old LJ: Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Nat Acad Sci USA 84: 2416-2420, 1987.
58. Cheresh DA, Harper JR, Schulz G, Reisfeld RA: Localization of the gangliosides GD3 and GD2 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81: 5767-5771, 1984.
59. Cheung N-KV, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45: 2642-2649, 1985.
60. Imam A, Mitchell MS, Modlin RL, Taylor CR, Kempf RA, Kan-Mitchell J: Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections. J Invest Dermatol 86: 145-148, 1986.
61. Kan-Mitchell J, Imam A, Kempf RA Taylor CR, Mitchell MS: Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res 46: 2490-2496, 1986.
62. James K, Bell GT: Human monoclonal antibody production current status and future prospects. J Immunol Method 100: 5-40, 1987.
63. Thompson KM: Human monoclonal antibodies. Immunol Today 9: 113-117, 1988.
64. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 125: 373-389, 1974.
65. Ludwig DS, Finkelstein RA, Karu AE, Dallas WS, Ashby ER, Schoolnik GK: Anti-idiotypic antibodies as probes of protein active sites: Application to cholera toxin subunit B. Proc Natl Acad Sci USA 84: 3673-3677.
66. Herlyn D, Wettendorff M, Iliopoulos D, Koprowski H: Functional mimicry of tumor-associated antigens by antiidiotypic antibodies. Exper Clin Immunogenet 5: 165-175, 1988.
67. O'Connell MJ, Chen ZJ, Yang H, Yamada M, Massaro M, Mittelman A, Ferrone S: Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. Semin Surg Oncol 5: 441-447, 1989.
68. Levy R, Miller RA: Therapy of lymphoma directed at idiotypes. Monogr J Natl Cancer Inst 10: 61-68, 1990.
69. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517-522, 1982.
70. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65: 1349-1363, 1985.
71. Raffeld M, Neckers L, Longo DL, Cossman J: Spontaneous alteration of idiotype in a monoclonal B cell lymphoma: Escape from the detection by anti-idiotype. N Engl J Med 312: 1653-1658, 1985.
72. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40: 3147-3154, 1980.
73. Neuberger MS, Rejewsky K, Switch from hapten-specific immunoglobulin M to immunoglobulin D secretion in a hybrid mouse cell line. Proc Natl Acad Sci USA 78: 1138-1142, 1981.
74. Capone PM, Papsidero ID, Chu TM: Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Cancer Inst 72: 673-677, 1984.
75. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R Eisen HN: Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 8648-8652, 1985.
76. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM: Specific targeting of cytotoxic T cells by anti-T3 linking to anti-target cell antibody. Nature (London) 316: 354-356 ,1985.
77. Nolan O, O'Kennedy R: Bifunctional antibodies: concept, production and applications. Biochim Biophys Acta 1040: 1-11, 1990.
78. Nolan O, O'Kennedy R: Bifunctional antibodies and their potential clinical applications. Int J Clin Lab Med 22: 21-27, 1992.
79. Fanger MW, Segal DM: Romet-Lemonne J, Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 12: 51-54, 1983.
80. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540, 1983.
81. Barr IG, MacDonald HR, Buchegger F, von Fliedner V: Lysis of tumour cells by the retargeting of murine cytotoxic T lymphocytes with bispecific antibodies. Int J Cancer 40: 423-429, 1987.
82. Menard S, Canevari S and Colnaghi MI: Hybrid antibodies in cancer diagnosis and therapy. Int J Biol Markers 4: 131-134, 1989.
83. Nitta T, Sato K, Yagita H, Okumura K, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-374, 1990.
84. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PCL, Feldmann M, Carter P: Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 175: 217-225, 1992.
85. Hnatowich DJ, Layne WW, Childs RL, Lanteigne D, Davis MA, Griffin TW, Doherty PW: Radioactive labeling of antibody: a simple and efficient method. Science 220: 613-615, 1983.
86. Shah SA, Gallagher BM, Sands H: Radioimmunodetection of small human tumor xenografts in spleen of athymic mice by monoclonal antibodies. Cancer Res 45: 5824-5829, 1985.
87. Sands H, Loveless SE: Biodistribution and pharmacokinetics of recombinant, human interleukin-2 in mice. Int J Immunopharmacol 11: 411-416, 1989.
88. Andres RY, Schubiger PA: Radiolabeling of antibodies. Methods and limitations. Nuklearmedicin 25: 162-166, 1986.
89. Ramjeesingh M, Zywulko M, Rothstein A, Whyte R, Shami EY: Antigen protection of monoclonal antibodies undergoing labelling. J Immunol Methods 133: 159-167, 1990.
90. Britton KE, Mather SJ, Granowska M: Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy Nucl Med Communicat 12: 333-347, 1991.
91. Goldenberg DM, DeLand EH, Kimm EE, Bennett S, Primus FJ, van Nagell JR, Jr, Estes N, DeSimone P, Rayburn D: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse tumors by external photoscanning. N Engl J Med 298: 1384-1388, 1978.
92. Mach J-P, Carrel S, Forni M, Ritschard J, Donath A, Alberto P: Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma. N Engl J Med 303: 5-10, 1980.
93. Mach J-P, Carrel S, Merenda C, Sordat B, Cerottini J-C: In vivo localization of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (London) 248: 704-706, 1974.
94. Mach J-P, Chatal J-F, Lumbroso J-D Buchegger F, Forni M, Ritschard J, Berche C, Douillard J-Y, Carrel S, Herlyn M, Steplewski Z, Koprowski H: Tumor localization in patients by radiolabeled monoclonal antibody against colon carcinoma. Cancer Res 43: 5593-5600, 1983.
95. Epenetos AA, Mather S, Granowska M: Targeting of iodine-123-labelled tumorassociated monoclonal antibodies to ovarian, breast and gastrointestinal tumors. Lancet 2: 999-1005, 1982.
96. Farrands PA, Pimm MV, Embleton MJ, Perkins AC, Hardy JD, Baldwin RW, Hardcastle JD: Radioimmunodetection of human colorectal cancers by an antitumor monoclonal antibody. Lancet 2: 397-404, 1482.
97. Fairweather DS, Bradwell AR, Dykes PW, Vaughan AT, Watson-James SF, Chandler S: Improved tumor localization using indium-111 labelled antibodies. Br Med J 287: 167-170, 1983.
98. 2 monoclonal antibody fragments. Radiology 149: 549-555, 1983.
99. Chatal J-F, Saccavini J-C, Fumoleau P, Douillard JY, Curtet C, Kremer M, Le Mevel B, Koprowski H: Immunoscintigraphy of colon carcinoma. J Nucl Med 25: 307-314, 1984.
100. Dillman R: Monoclonal antibodies in the treatment of cancer. CRC Crit Rev Oncol Hematol 1: 357-385, 1984.
101. Moldofsky PJ, Sears HF, Mulhern CBJr, Hamond ND, Powe J, Gatenby RA, Steplewski Z, Koprowski H: Detection of metastatic tumor in normal sized retroperitoneal lymph nodes by monoclonal antibody imaging. N Engl J Med 311: 106-107, 1984.
102. Delaloye B, Delaloye-Bischof A, Dudczak ER, Koppenhagen K, Mata F, Penafiel A, Maul FD, Pasquier J: Clinical comparison of 99mTc-HMDP and 99mTc-MDP. A multicenter study. Eur J Nucl Med 11: 182-185, 1985.
103. 2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 77: 301-311, 1986.
104. Rainsbury RM, Westwood JH, Coombes RC: Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111. Lancet 2: 934-938, 1983.
105. 131-I-labeled monoclonal antibodies. J Nucl Med 24: 123-123, 1983.
106. Larson SM, Carrasquillo JA, Krohn KA, McGuffin RW, Williams DL, Hellstrom I, Lyster D: Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies. JAMA 249: 811-812, 1983.
107. 131I-labeled p96-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 2: 2101-2114, 1983.
108. 111In 96.5 monoclonal antibody: A preliminary report. Radiology 155: 493-499, 1985.
109. 111In-labeled monoclonal antibody 96.5. Cancer Res 45: 2376-2381, 1985.
110. 111-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res 45: 2382-2386, 1985.
111. 2 fragments. Cancer Res 45: 3378-3387, 1985.
112. 131I- CC49 and interferon-gamma. Diseas Col Rect 37(suppl 2): S100-S105, 1994.
113. 212Bi-anti-Tac. Cancer Res 54: 4362-4370, 1994.
114. Berche C, Mach J-P, Lumbroso J-D, Langlais C, Aubry F, Buchegger F, Carrel S, Rougier P, Parmentier C, Tubiana M: Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Brit Med J 285: 1447-1451, 1982.
115. Mach J-P, Buchegger F, Forni M, Ritschard J, Carrel S, Egley R, Donath A, Rohner A: Immunoscintigraphy of human carcinoma after injection of radiolabele monoclonal anti-carcinoembryonic antigen antibodies. Curr Top Microbiol Immunol 104: 49-55, 1983.
116. Casellas P, Brown JP, Gros O, Gros P, Hellstrom I, Jansen FK, Poncelet P, Roncucci R, Vidal H, Hellstrom KE: Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int J Cancer 30: 437-443, 1982.
117. Bumol TF, Want QC, Reisfeld RA, Kaplan NO: Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci (Biol) 80: 529-533, 1983.
118. Trowbridge IS, Domingo D: Anti-transferrin monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature (London) 294: 171-173, 1981.
119. Watanabe Y, Miyazaki H, Osawa T: Effect of a monoclonal anti-carcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen- producing tumor cells. J Pharm Dyn 7: 593-603, 1984.
120. Griffin TW, Haynes LR, Demartino JA: Selective cytotoxicity of a ricin A-chain- anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line. J Natl Cancer Inst 69: 799-805, 1982.
121. Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PCL Neville DM Jr Youle RJ: Anti-T cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies. Science 222: 512- 515, 1983.
122. Casellas P, Bourrie BJ, Gros P, Jansen FK: Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 259: 9359-9364, 1984.
123. Fitzgerald DJP, Waldmann TA, Willingham MC, Pastan I: Pseudomonas exotoxin-anti-TAC. J Clin Invest 74: 966-971, 1984.
124. Ramakrishnan S, Houston LL: Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: Potentiation by chloroquine. Science 223: 58-61, 1983.
125. Raso V, Ritz J, Basala M, Schlossman SF: Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing common acute lymphoblastic antigen. Cancer Res 42: 457-464, 1985.
126. Myers CD, Thorpe PE, Ross WJC, Cumber AJ, Kate FE , Tax W, Geavers MF: An immunotoxin with therapeutic potential in T cell leukemia: WT1 ricin A. Blood 63: 1178-1185, 1984.
127. Seon BK: Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res 44: 259-264, 1984.
128. Durrant LG, Byers VS, Scannon PJ, Rodvien R, Grant K, Robins RA, Marksman RA, Baldwin RW: Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin Exp Immunol 75: 258-264, 1989.
129. Blakey DC, Thorpe PE: Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins. Scand J Rheumatol Suppl 76: 279-287, 1988.
130. Pastan I, Fitzgerald D: Recombinant toxins for cancer treatment. Science 254: 1173-1177, 1991.
131. Gilliland DG, Steplewski Z, Collier J, Mitchell KF, Chang TH, Koprowski H: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77: 4539-4543, 1980.
132. Houston LL, Nowinski RC: Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against Thy 1.1 antigen. Cancer Res 41: 3913-3917, 1981.
133. Blythman HE, Casellas P, Gros O, Gros P, Jansen FK, Paolucci F, Pan B, Vidal H: Immunotoxins: Hybrid molecules of monoclonal anti odies and a toxin subunit specifically kill tumor cells. Nature (London) 290: 145-146, 1981.
134. Vitetta ES, Krolick KA, Uhr JW: Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev 62: 159-183, 1982.
135. Thorpe PE, Ross WCJ: The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62: 119-158, 1982.
136. Knowles PP, Thorpe PE: Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal Biochem 160: 440-443, 1987.
137. Cumber AJ, Forrester JA, Foxwell BM, Ross WC, Thorpe PE: Preparation of antibody-toxin conjugates. Meth Enzymol 112: 207-225, 1985.
138. Moolten FL, Capparell NJ, Zajdel SH: Antitumor effects of antibody-diphteria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40. J Natl Cancer Inst 55: 473-477, 1975.
139. Bernhard MI, Foon KA, Oeltmann TN, Key ME, Huang M, Clarke GC, Christensen WL, Hoyer LC, Hama MGJr, Oldham RK: Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphteria toxin A chain. Cancer Res 43: 4420-4428, 1983.
140. Chang T, Dazord A, Neville DMJr, Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide complex. J Biol Chem 252: 1515-1522, 1977.
141. Dumontet C, Immunotherapy and cancer: the role of monoclonal antibodies. J Chir (Paris) 126: 682-686, 1989.
142. Youle RJ, Colombatti M: Immunotoxins: monoclonal antibodies linked to toxic proteins for bone marrow transplantation and cancer therapy. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment, ed. JA Roth, Futura Publishing Company, Inc Mount Kisco New York 1986, pp. 173-213.
143. Moller G, (ed.): Antibody carriers of drugs and toxins in tumor therapy. Immunol Rev 62: 1-216, 1982.
144. Byers VS, Baldwin RW: Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 65: 329-335, 1988.
145. Pietersz GA, Krauer K: Antibody-targeted drugs for the therapy of cancer. J Drug Target 2: 183-215, 1984.
146. Redwood WR, Tom TD, Strand M: Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res 44: 5681-5687, 1984.
147. Ferens JM, Krohn KA, Beaumier PL: High level iodination of monoclonal antibody fragments for radiotherapy. J Nucl Med 25: 367-3701, 1984.
148. Oldham RK: Custom-tailored drug immunoconjugates in cancer therapy. Mole Biother 3: 148-162, 1991.
149. Zhen Y, Peng Z, Deng Y, Xu H, Chen Y, Tian P, Li D, Jiang M: Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody. Chinese Med Sciences J 9: 75-80, 1994.
150. Sivam GP, Martin PJ, Reisfeld RA, Mueller BM: Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 55: 2352-2356, 1995.
151. Clauss MA, Jain RK: Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 50: 3487-3492, 1990.
152. Dykes PW, Bradwell AR, Chapman CE, Vaughan ATM: Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev 14: 87-106, 1953.
153. Swabb EA, Wei J, Gullino PM: Diffusion and convection in normal and neoplastic tissues. Cancer Res 34: 2814-2822, 1974.
154. Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6: 559-594, 1987.
155. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051, 1987.
156. Jain RK: Delivery of novel therapeutic agents in tumors: physiological harriers and strategies. J Natl Cancer Inst 81: 570-576, 1989.
157. Chary SR, Jain RK: Direct measurements of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci USA 6: 5385-5389, 1989.
158. Levy RL, Miller RA: Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies. Ann Rev Med 34: 107-116, 1983.
159. Dillman RL, Beauregard JC, Sobol RE, Royston I, Bartholomew RM, Hagan PS, Halpern SE: Lack of radioimmunodetection and complications associated with monoclonal anti-carcinoembryonic antigen: Antibody crossreactivity with an antigen on circulating cells. Cancer Res 44: 2213-2218, 1984.
160. Dillman RO, Shawler DL, Dillman JB: Therapy of chronic lymphocytic leukemia and cutaneous T cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2: 881-8911, 1984.
161. Foon KA, Schroff RW, Bunn A, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ, Herberman RB, Oldham RK: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64: 1085-1093, 1984.
162. Shawler DL, Bartholomew RM, Smith LM, Dillman RO: Human immune response to multiple injections of murine monoclonal Ig. J Immunol 135: 1530-1535, 1985.
163. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC: Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 5: 879-885, 1985.
164. Stevenson FK, George AJ, Glennie MJ: Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol 48: 126-166, 1990.
165. Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal Schlossman SF: Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141-152, 1981.
166. Ball ED, Bernier GM, Cornwell GG: Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood 62: 1203-1210, 1984.
167. Sears HF, Herlyn D, Steplewski Z Koprowski H: Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 3: 138-150, 1984.
168. Sears HF, Herlyn D, Steplewski Z, Koprowski H: Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45: 5910-5913, 1985.
169. Bellet D, Bidart JM, Rougier P, Bohuon C: Use of monoclonal antibodies in the treatment of cancer of the pancreas: towards new progress? Bull Cancer (Paris) 77: 283-288, 1990.
170. Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PC, Fer M, Schoenberger CS, Farrell M, Kimball E, Sherwin SA: Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 2: 1235-1244, 1984.
171. Houghton AN, Gordon-Curdo C Eisinger M: Differentiation antigens of melanoma and melanocytes. Int Rev Exp Pathol 28: 217-248, 1986.
172. Goodman GE, Beaumier P, Hellstrom I, Fernyhough B, Hellstrom KE: Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3: 340-352, 1985.